Market Dynamics

Increasing incidences of bird deaths due to various infection of virus across the globe and rise in government spending on development of better solutions are major factors expected to drive the growth of global bird flu treatment market. According to U.S. Department of Health & Human Services more than 700 human infections with Asian HPAI H5N1 viruses have been reported to WHO from primarily 15 countries in Asia, Africa, the Pacific, Europe and the Near East since November 2003. In India bird flu reported among wild geese in Himachal Pradesh, crows in Rajasthan and Madhya Pradesh and ducks in Kerala. In Haryana, around one lakh poultry birds died mysteriously in 2021. Government of developed and developing countries is spending high for the development of present infrastructure in order to support the R&D activities. In addition, major players are focused on shifting the production units to developing countries due to low cost labor & easy availability of raw material. These are factors expected to augment the growth of global bird flu treatment market. Drug manufacturers approach towards introduction of innovative solution in order to attract new customer and enhance the business is expected to impact the growth of target market. In 2020, Novacyt Group a biotechnology company launched research-use-only (RUO) polymerase chain reaction (PCR) tests for avian influenza (aka bird flu) following recent outbreaks across Europe. This product launch is expected to help the company to enhance the business and increase the revenue share. Government of developing countries is taking various efforts in order to lower the impact of the bird flu. They are increasing the awareness among consumer related to incorporating bio-security principles and practice hygiene.

Government of emerging economies is providing various business policies with the focus to attract drug manufacturers and strengthen the regional manufacturing capabilities. Emergence of small and mid-size enterprises with innovative solutions is expected to boost the growth of bird flu treatment market. Factors such as high cost associated to R&D and manufacturing and stringent government regulations related to product approval are expected to hamper the growth of global bird flu treatment market. In addition, lack of developed infrastructure in developing countries is expected to limit the R&D capabilities further challenging the growth of bird flu treatment market. However, increasing investment by major players for product development and increasing government spending on infrastructure development are factors expected to create new opportunities for players operating in the target market. In addition, increasing partnership between regional and international players is expected to support the revenue transaction of the bird flu treatment market.

Segment Analysis by Region

The market in Asia Pacific is expected to account for major revenue share in the global bird flu treatment market due to increase case of bird flu infection. In addition, increasing awareness activities by the government and deployment of preventive measures by providing antiviral, neuraminidase inhibitors, and ion channelM2 blockers through hospitals to consumers are factors expected to support the growth of bird flu treatment regional market.

Increasing merger & acquisition activities by major players in order to enhance the business and increase the revenue share is another factor expected to boost the bird flu treatment market growth.

Competitive Landscape      

The global bird flu treatment market is high highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.

Report coverage

Bird Flu Treatment Market Segment Analysis, 2019

The global bird flu treatment market is segmented into drug type and end use. The drug type segment is bifurcated into antiviral, combination treatment, prophylactic antibiotics, steroids and other immunosuppressants, immunoglobulin, and ribavirin. Among the drug type antiviral segment is expected to account for moderate revenue share in the bird flu treatment market. The end use segment is divided into hospital, institutional health centers, and clinics. Among the end use the hospital segment is expected to account for major revenue share in the target segment. The players profiled in the report Sanofi, GlaxoSmithKline plc, Forrest Pharmaceutcals Inc., Macleods Pharmaceuticals Ltd., F. Hoffmann-La Roche Ltd, BioCryst Pharmaceuticals, and Gilead Sciences Inc.

Market Segmentation

Market By Type

Antiviral

Neuraminidase inhibitors

Ion channelM2 blockers

Combination treatment

Prophylactic antibiotics

Steroids and other immunosuppressants

Immunoglobulin

Ribavirin

Market By End Use

Hospital

Institutional Health Centers

Clinics

Market By Region

North America

• U.S.
• Canada

Europe

• U.K.
• Germany
• France
• Spain
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia-Pacific

Latin America

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC
• South Africa
• Rest of Middle East & Africa